Current status and challenges of TCR-T cell therapy for AML/MDS

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Survival rates for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain suboptimal despite recent therapeutic advancements.
• Current immunotherapy approaches for AML/MDS face challenges due to a lack of uniformly expressed cell-surface targets and HLA restrictions, limiting efficacy.
• Novel therapeutic strategies with distinct mechanisms of action are crucial for improving patient outcomes in these hematologic malignancies.

Purpose of the Study:

• To review the development process of T-cell receptor (TCR) T-cell therapy.
• To summarize recent clinical trials involving TCR T-cell therapy for AML and MDS.
• To discuss the future perspectives and potential of TCR T-cell therapy in treating AML and MDS.

Main Methods:

• Literature review of T-cell receptor (TCR) T-cell therapy development.
• Analysis of clinical trial data for immunotherapy in AML and MDS.
• Exploration of patient selection strategies based on target antigen expression.

Main Results:

• T-cell receptor (TCR) T-cell therapy development involves complex processes.
• Recent clinical trials indicate potential but also highlight challenges in patient eligibility and target expression.
• Careful patient selection based on high and homogeneous target antigen expression may serve as a predictive biomarker.

Conclusions:

• T-cell receptor (TCR) T-cell therapy represents a promising avenue for treating AML and MDS.
• Optimizing patient selection is critical for maximizing the efficacy of TCR T-cell therapy.
• Further research and clinical trials are needed to overcome existing limitations and expand the application of this immunotherapy.